In The Know

Introducing CiiTA’s Free Duplicate Discount Risk Assessment

At present most manufacturers are not actively or effectively managing their exposure to 340B duplicate discounts. Current projections of the scope of the issue are severely limited by a lack of data, and many manufacturers are completely unaware of the significance of the problem. Additionally, the data required to identify duplicate claims is difficult to…

Read More

CiiTA Managing Partner to Speak at National Leadership Summit on 340B

PORTLAND, Ore. – April 25, 2016 — CiiTA founder and managing partner Jason Hardaway is invited to speak at the upcoming third-annual National Leadership Summit on 340B in Washington, D.C. on May 17, 2016. This summit is the annual opportunity for stakeholders to engage in meaningful and transparent dialogue to ensure the 340B program’s future…

Read More

CiiTA Managing Partner Jason Hardaway to Speak at CBI’s GPO, 340B and Class of Trade Conference in Philadelphia

For Immediate Release PORTLAND, Ore. – March 10, 2016 — CiiTA founder and managing partner Jason Hardaway has been invited to speak at the upcoming CBI GPO Membership, 340B and Class of Trade Management conference on March 23 & 24 in Philadelphia. This conference is Bio/Pharma’s premier event on roster management, class of trade verification…

Read More

CiiTA Managing Partner: Risk to Manufacturers Letter to the Editor

The P&T (Pharmacy and Therapeutics) Community online journal has published a response by CiiTA’s Managing Partner, Jason Hardaway, to their October 2015 report by Stephen Barlas about Congress’s 340B Program omnibus guidance issued by the Health Resources and Services Administration (HRSA). Mr. Hardaway’s article, titled 340B Program Puts Manufacturers At Risk of Duplicate Drug Discounts, addresses the material and financial risk of duplicate…

Read More

CiiTA is Concerned for Covered Entities

It should come as no surprise that CiiTA fully supports the 340B Program and recognizes the important financial role it plays in the healthcare safety net. What might be less obvious is that the vast majority of pharmaceutical manufacturers support 340B as well. (Full disclosure: CiiTA’s client base is almost exclusively drug companies.) The 340B…

Read More

340B/Medicaid Duplicate Discount Risk is Greater Than Ever

Over the past year, we here at CiiTA have become increasingly concerned about the potential 340B/Medicaid duplicate discount risk to manufacturers. We recently looked into this for a couple of our clients and found what amounts to a perfect storm of insidious financial exposure: 1) a surge in eligible claims thanks to the ACA-directed Medicaid…

Read More

Ryan White CARE Act Celebrates 25th Anniversary

Tuesday, August 18, 2015 marked the 25th anniversary of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, the legislation that created the most comprehensive Federal program that provides services exclusively to people living with HIV. On August 18, 1990, President Bush signed the groundbreaking Ryan White CARE Act that passed Congress with overwhelmingly bipartisan…

Read More

CMS Proposes Rule: 340B onus now on Medicaid MCOs

On May 26, 2015 the Centers for Medicare & Medicaid Services (CMS) proposed to make Medicaid managed care organizations (MCOs) responsible for establishing procedures to prevent 340B duplicate discounts in the managed Medicaid setting. In the proposed rule, CMS has clarified that the onus will fall solely on the MCO to create models to prevent…

Read More

Managing Partner of CiiTA, LLC invited as panelist at 2015 National Leadership Summit on 340B

Jason Hardaway, CiiTA, LLC’s Managing Partner, has been invited as a panelist and discussion leader for a special session of the second annual National Leadership Summit on 340B. Held June 11, 2015 in Washington, DC, the invitation-only event will provide the opportunity for stakeholders to come together to engage in meaningful and transparent dialogue to ensure the…

Read More

CiiTA, LLC Company Blog

Welcome to the CiiTA, LLC company blog – your resource for judicious, topical information related to the PHS 340B Drug Pricing Program. At CiiTA, we believe 340B is a critical part of the United States’ healthcare safety net, and as it experiences unprecedented and relatively unchallenged growth, we labor to stay ahead of the curve so that we can continue to teach our clients what even they don’t know that they don’t know. Our portfolio of services and products are designed around sustaining the 340B Program while mitigating untoward behavior within the program.

CiiTA focuses exclusively on the manufacturer and their participation in the 340B Program. We are outspoken about protecting the 340B Program by making it sustainable and transparent. To that end, this blog will bring you all the news and emerging policies about the program. (Note: for more in-depth articles about the program, please consider subscribing to The Synapse, a subscription-based report published bi-monthly with additional updates targeting specific events and market needs related to a particular 340B Program topic.)

Read More

Develop Your 340B Strategy

CiiTA has, through extensive experience, developed a set of best practices to help guide you through the creation of your 340B strategy. Download our process document to facilitate the development of your strategy.

Please enter your name.
Please enter a valid email address.
Something went wrong. Please check your entries and try again.